Description: Indacaterol (formerly known as QAB-149) is an anti-COPD drug acting as an ultra-long-acting β-adrenoceptor agonist developed by Novartis with pKi of 7.36. Indacaterol was approved in 2009 by FDA for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. Indacaterol inhibits cAMP production in Chinese hamster ovary cells stably transfected with human β2 adrenoceptors with pEC50 of 8.06.

References: J Pharmacol Exp Ther. 2006 May;317(2):762-70; J Pharmacol Exp Ther. 2008 Jan;324(1):270-5.

Related CAS #: 753498-25-8 (malate) 312753-06-3 (free base)

纯度：≥98%

CAS：312753-06-3